FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases PR Newswire TIRAT CARMEL, Israel, October 22, 2012 TIRAT CARMEL, Israel, October 22, 2012 /PRNewswire/ -- ®ExAblate MRI-guided Focused Ultrasound is effective in reducing pain from bone metastases in patients who could not undergo radiation therapy; Patients reported significant improvement in well-being, function, and reduction in medication use InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non- invasive, outpatient, therapy for uterine fibroids. To view the Multimedia News Release, please click: http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate Bone metastases occur when cancer cells break away from their primary site and spread to other parts of the body. "Pain is the most common and severe symptom of bone metastases, often causing significant physical and emotional discomfort with a large impact on enjoyment of life," says Mark Hurwitz, M.D.